Valo Therapeutics Oy, a Helsinki, Finland-based cancer immunotherapy company, received EUR 19M in funding.
The round consisted of €13M co-led by Indaco Venture Partners and CDP Venture Capital SGR with participation from Fondazione ENEA Tech e Biomedical. They joined the completed €6M investment round from Australian investors, supported by Freeman Road, bringing the total fundraising up to €19M.
The company intends to use the funds to expand and complete the Phase 1B clinical study of its lead tumour antigen-coated oncolytic virus candidate. Part of the investment round will be invested in Italy and allocated to the activities of the newly created Italian operating company, Valo Therapeutics Italy Srl, which will be based in Naples, with the aim of carrying out specific activities in the territory of Southern Italy such as (i) enrolling and treating patients in Southern Italy, (ii) initiating the large scale manufacturing of virus supporting product development up to the commercial phase, and (iii) supporting research activities in Institutions based in Naples and south of Italy.
Led by David Hinton, Valo Therapeutics (ValoTx) is an immunotherapy company developing tumor antigen-coated replication-competent viruses as therapeutic vaccines against cancer. Its lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki to turn oncolytic adenoviruses into activators of systemic anti-tumor cytotoxic T-cell immunity without the need to generate and manufacture multiple genetically modified viruses.
The company is also developing PeptiCHIP, a microchip-based solution that enables tumor neoantigen identification from very small tumor biopsies.
FinSMEs
10/03/2025